Sunitix 25 mg contains Sunitinib, an oral multi-targeted tyrosine kinase inhibitor (TKI) that exerts anti-tumor and anti-angiogenic effects. Sunitinib works by inhibiting multiple receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis (formation of new blood vessels), and metastatic progression. These include VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, KIT, FLT3, RET, and CSF-1R. By blocking these pathways, Sunitix disrupts the blood supply necessary for tumor survival and growth, and directly inhibits tumor cell proliferation.

Sunitix is indicated for the treatment of various solid tumors and advanced cancers, helping to control disease progression, reduce tumor size, and improve patient outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Sunitix 25 mg is indicated for the treatment of:

• Advanced Renal Cell Carcinoma (RCC) – for patients with unresectable or metastatic disease

• Gastrointestinal Stromal Tumors (GIST) – in patients whose disease is resistant to or intolerant of imatinib

• Pancreatic Neuroendocrine Tumors (pNET) – for progressive, unresectable, locally advanced or metastatic disease

• Other malignancies as determined by the treating oncologist, based on evidence of efficacy and clinical judgment

Sunitix may also be used in combination with other approved therapies as part of clinical protocols or physician-directed regimens.

Therapeutic Class

• Tyrosine Kinase Inhibitor (Multi-targeted TKI)

Pharmacology and Mode of Action

Sunitinib selectively inhibits multiple RTKs critical for tumor angiogenesis and proliferation:

• VEGFR-1, VEGFR-2, VEGFR-3: Reduces formation of new blood vessels to starve tumors

• PDGFR-α and PDGFR-β: Inhibits signaling in tumor stroma and vascular support

• KIT, FLT3, RET, CSF-1R: Directly suppresses tumor cell growth and survival

Sunitinib demonstrates both anti-proliferative and anti-angiogenic activity, which contributes to tumor regression and disease stabilization.

• Absorption: Well absorbed orally; peak plasma concentration within 6–12 hours

• Metabolism: Primarily metabolized in the liver via CYP3A4

• Elimination: Excreted in feces (~61%) and urine (~16%)

• Half-life: Approximately 40–60 hours

Dosage & Administration

• Standard Dose: 25–50 mg orally once daily, typically in cycles of 4 weeks on treatment followed by 2 weeks off (4/2 schedule)

• Dose Adjustment: Based on toxicity, side effects, hepatic or renal impairment, and patient tolerability

• Administration: Swallow capsules whole; can be taken with or without food

• Monitoring: Periodic blood counts, liver and kidney function tests, blood pressure, and cardiac monitoring are recommended

Special Populations:

• Hepatic Impairment: Dose modification may be necessary

• Renal Impairment: Usually safe, but monitor kidney function

• Pediatric Use: Safety and efficacy not established in patients under 18 years

Drug Interactions

• CYP3A4 Substrates: Strong inhibitors (e.g., ketoconazole, clarithromycin) may increase systemic exposure

• CYP3A4 Inducers: (e.g., rifampicin, phenytoin) may reduce efficacy

• Concomitant anticoagulants, antihypertensives, or drugs affecting QT interval require monitoring

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Hypersensitivity to Sunitinib or any of its excipients

• Severe uncontrolled hypertension or cardiovascular disease

Side Effects

Common adverse reactions include:

• Fatigue, diarrhea, nausea, vomiting, stomatitis

• Hypertension, hand-foot syndrome, skin discoloration, rash

• Hematologic effects: thrombocytopenia, neutropenia, anemia

• Cardiovascular events: QT prolongation, left ventricular dysfunction

• Hepatotoxicity and rare severe liver injury

Precautions & Warnings

• Monitor blood pressure, CBC, liver function, and cardiac function regularly

• Patients with cardiovascular risk factors should be closely monitored

• Potential risk of bleeding, gastrointestinal perforation, and thyroid dysfunction

• Dose interruption or reduction may be required for severe adverse events

Pregnancy & Lactation

• Pregnancy: Category D – may cause fetal harm; use effective contraception

• Lactation: Breastfeeding is not recommended during therapy

Storage Conditions

• Store below 30°C in a cool, dry place

• Keep capsules in the original container, away from light and moisture

• Keep out of reach of children.